Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Dec;50(12):930–933. doi: 10.1136/ard.50.12.930

Clinical experience with pamidronate in the treatment of Paget's disease of bone.

S J Gallacher 1, B F Boyce 1, U Patel 1, A Jenkins 1, S H Ralston 1, I T Boyle 1
PMCID: PMC1004585  PMID: 1768163

Abstract

Bisphosphonates have been shown to be effective in treating the increased bone turnover associated with Paget's disease of bone. In this study two groups of patients were treated with pamidronate by intravenous infusion. In group 1 (n = 15) 30 mg of pamidronate was given once a week for six weeks. A subgroup (group 1A, n = 6) of more severely affected patients (pretreatment serum alkaline phosphatase (ALP) greater than 1000 U/l, normal range 80-280 U/l) received a further 60 mg weekly for three weeks. Group 2 (n = 24) received 45 mg of pamidronate every three months for one year. In both groups the level of ALP in serum samples decreased steadily throughout the year. In group 1 the level decreased to a mean value of 230 U/l (95% confidence interval 188-281) and in group 2 to 297 U/l (227-389). Four of the six patients in group 1A achieved normal ALP, whereas ALP remained at an increased level in all of the 10 patients in group 2 whose pretreatment ALP was greater than 1000 U/l, suggesting that a dose-response effect exists. The lowest hydroxyproline to creatinine ratios (normal ratio less than 0.033) were observed at the end of treatment in group 1, with a mean ratio of 0.022 (range 0.015-0.033) and at three months after the start of treatment in group 2 with a mean ratio of 0.029 (range 0.022-0.037). There was a significant decrease in the turnover of bone, as measured by whole body retention of radiolabelled bisphosphonate, from a mean of 49.3 to 41.0% (p less than 0.01). These data confirm that pamidronate is effective in the management of Paget's disease of bone. For patients with levels of ALP in serum samples of up to four times above the upper limit of the normal reference range, an effective and convenient regimen is 45 mg every three months for one year. For patients with higher levels of ALP higher doses may be more effective.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyce B. F., Smith L., Fogelman I., Johnston E., Ralston S., Boyle I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984 Apr 14;1(8381):821–824. doi: 10.1016/s0140-6736(84)92272-4. [DOI] [PubMed] [Google Scholar]
  2. Cantrill J. A., Anderson D. C. Treatment of Paget's disease of bone. Clin Endocrinol (Oxf) 1990 Apr;32(4):507–518. doi: 10.1111/j.1365-2265.1990.tb00892.x. [DOI] [PubMed] [Google Scholar]
  3. Cantrill J. A., Buckler H. M., Anderson D. C. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone. Ann Rheum Dis. 1986 Dec;45(12):1012–1018. doi: 10.1136/ard.45.12.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DeRose J., Singer F. R., Avramides A., Flores A., Dziadiw R., Baker R. K., Wallach S. Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment. Am J Med. 1974 Jun;56(6):858–866. doi: 10.1016/0002-9343(74)90815-8. [DOI] [PubMed] [Google Scholar]
  5. Delmas P. D., Chapuy M. C., Vignon E., Charhon S., Briancon D., Alexandre C., Edouard C., Meunier P. J. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab. 1982 Apr;54(4):837–844. doi: 10.1210/jcem-54-4-837. [DOI] [PubMed] [Google Scholar]
  6. Fogelman I., Smith L., Mazess R., Wilson M. A., Bevan J. A. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986 Jan;24(1):57–62. doi: 10.1111/j.1365-2265.1986.tb03254.x. [DOI] [PubMed] [Google Scholar]
  7. Frijlink W. B., Bijvoet O. L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):799–803. doi: 10.1016/s0140-6736(79)91318-7. [DOI] [PubMed] [Google Scholar]
  8. Gallacher S. J., Ralston S. H., Patel U., Boyle I. T. Side-effects of pamidronate. Lancet. 1989 Jul 1;2(8653):42–43. doi: 10.1016/s0140-6736(89)90277-8. [DOI] [PubMed] [Google Scholar]
  9. Goverde B. C., Veenkamp F. J. Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis. Clin Chim Acta. 1972 Oct;41:29–40. doi: 10.1016/0009-8981(72)90492-5. [DOI] [PubMed] [Google Scholar]
  10. Harinck H. I., Papapoulos S. E., Blanksma H. J., Moolenaar A. J., Vermeij P., Bijvoet O. L. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 1987 Nov 21;295(6609):1301–1305. doi: 10.1136/bmj.295.6609.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heath D. A. Treating Paget's disease. Br Med J (Clin Res Ed) 1987 Apr 25;294(6579):1048–1050. doi: 10.1136/bmj.294.6579.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Meunier P. J., Chapuy M. C., Alexandre C., Bressot C., Edouard C., Vignon C., Mathieu L., Trechsel U. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet. 1979 Sep 8;2(8141):489–492. doi: 10.1016/s0140-6736(79)91551-4. [DOI] [PubMed] [Google Scholar]
  13. Mundy G. R., Martin T. J. The hypercalcemia of malignancy: pathogenesis and management. Metabolism. 1982 Dec;31(12):1247–1277. doi: 10.1016/0026-0495(82)90012-9. [DOI] [PubMed] [Google Scholar]
  14. Ralston S. H., Gardner M. D., Dryburgh F. J., Jenkins A. S., Cowan R. A., Boyle I. T. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet. 1985 Oct 26;2(8461):907–910. doi: 10.1016/s0140-6736(85)90848-7. [DOI] [PubMed] [Google Scholar]
  15. Ryan W. G. Treatment of Paget's disease of bone with mithramycin. Clin Orthop Relat Res. 1977;(127):106–110. [PubMed] [Google Scholar]
  16. Tan T. T., Alzaid A. A., Sutcliffe N., Gardner M. D., Thomson J. A., Boyle I. T. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate. Postgrad Med J. 1988 Mar;64(749):224–227. doi: 10.1136/pgmj.64.749.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Thiébaud D., Jaeger P., Gobelet C., Jacquet A. F., Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med. 1988 Aug;85(2):207–212. doi: 10.1016/s0002-9343(88)80344-9. [DOI] [PubMed] [Google Scholar]
  18. Thiébaud D., Jaeger P., Jacquet A. F., Burckhardt P. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol. 1988 May;6(5):762–768. doi: 10.1200/JCO.1988.6.5.762. [DOI] [PubMed] [Google Scholar]
  19. Vega E., Gonzalez D., Ghiringhelli G., Mautalen C. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease. J Bone Miner Res. 1987 Aug;2(4):267–271. doi: 10.1002/jbmr.5650020402. [DOI] [PubMed] [Google Scholar]
  20. Woodhouse N. J., Mohamedally S. M., Saed-Nejad F., Martin T. J. Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment. Br Med J. 1977 Oct 8;2(6092):927–929. doi: 10.1136/bmj.2.6092.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yates A. J., Jones T. H., Mundy K. I., Hague R. V., Brown C. B., Guilland-Cumming D., Kanis J. A. Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) 1984 Oct 27;289(6452):1111–1112. doi: 10.1136/bmj.289.6452.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yates A. J., Percival R. C., Gray R. E., Atkins R. M., Urwin G. H., Hamdy N. A., Preston C. J., Beneton M. N., Russell R. G., Kanis J. A. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet. 1985 Jun 29;1(8444):1474–1477. doi: 10.1016/s0140-6736(85)92253-6. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES